Etigilimab with Nivolumab in Locally Advanced or Metastatic Solid Tumors - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drugs, etigilimab and nivolumab, are safe and effective for fighting your cancer.

What is the Condition Being Studied?

Solid Tumors

Who Can Participate in the Study?

Adults with cancer that:
- Consists of solid tumors
- Is recurrent, locally advanced, or metastatic

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get the study drugs, etigilimab and nivolumab, by I.V. once every 2 weeks
- Give blood and urine samples
- Have regular CT or MRI scans

Study Details

Full Title
A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107599
NCT: NCT04761198
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698